drugset / Trial / NCT02204098
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Phase 1
Active not recruiting
27 enrolled
Washington University School of Medicine
Rising Tide Foundation · collabUnited States Department of Defense · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to find out about the safety of injecting the gene (DNA) for mammaglobin-A into people with breast cancer. The DNA used in this study was purified from bacteria and contains the gene for mammaglobin-A. Mammaglobin-A is a protein that is highly expressed by breast cancer cells. Injection of mammaglobin-A DNA may be a way to generate an immune response to breast cancer cells. There is evidence that an immune response may be a way to fight cancer. In addition to evaluating the safety of the mammaglobin-A injection, this study is also looking at the immune response that the participant's body has after each injection.
Timeline
- Start
- 2015-01-07
- Primary completion
- 2022-04-06
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mammaglobin-A DNA Vaccine | Vaccine | 4 mg | Other |